Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Floor

KRAS

Clinical trial

51 people · 66 posts · 5 abstracts

Heat trend for this story

Heat now 4·Peak in the comparable set 5 (Apr 23 04:00)·Change over 24h in the comparable set –·Participants now 6

Participants counted6
0246
Heat over time
0246Apr22Apr23Apr23Apr23

First-generation G12C drugs (sotorasib, adagrasib) bind KRAS in the off state. After treatment, RTK feedback reloads KRAS into the on state.

Other cases in this chapter
  • daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
  • daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
  • zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
  • VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
  • elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
  • RM-055Active in daraxonrasib-resistant and RAS-amplification models
Evidence
1884

Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models.

Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz

5996

Evaluating the effects of the Pan-KRas inhibitor RMC-6236 in KRas-mutant colorectal cancer cells

Seema nadir, Sumaiya Binte Hamid, Mati Ur Rehman, Azhar Hussain Rajabali, Kulsoom K. Ghias, Arooj Shafiq

7100NCT06500676NCT07020221

VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents

Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter

CT129

Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors

Ahmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov

CT303NCT05410145

Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study

Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque

Floor
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org